RNA, U6atac small nuclear 17, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC17P profile across patient tissues and cancer cell-line models. RNU6ATAC17P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC17P is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, RNU6ATAC17P RNA expression shows 6,925 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where RNU6ATAC17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC17P survival associations across molecular data types. RNU6ATAC17P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC17P RNA expression–survival associations across cancer types. High RNU6ATAC17P expression shows unfavorable associations in UVM, ACC, BLCA, DLBC and SKCM, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .015). Together, the overview and detailed table identify KIRP as the clearest survival context for RNU6ATAC17P RNA expression.
This table summarizes RNU6ATAC17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC17P shows lower tumor expression in KIRP and higher tumor expression in LIHC and LUAD. The KIRP box plot shows higher RNU6ATAC17P RNA expression in normal versus tumor tissue (log2 FC = −0.415, t-test p = .025).
This table shows molecular features associated with RNU6ATAC17P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC17P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
